# Symphony Environmental optimistic that future performance will improve materially during 2022 and beyond

- Link: https://www.directorstalkinterviews.com/symphony-environmental-optimistic-that-future-performance-will-improve-materially-during-2022-and-beyond/4121058998
- Published: 2022-03-30T07:42:51+01:00
- Author: Amilia Stone

**Symphony Environmental Technologies Plc** ([LON:SYM](https://www.directorstalkinterviews.com/company/symphony-environmental-technologies-plc/sym.l))
global specialists in technologies that make plastic and rubber products “smarter,
safer and sustainable”, has announced its preliminary results for the year ended
31 December 2021.

**Financial highlights:**

·      Group revenues £9.16 million (2020: £9.77 million), lower principally due
to £0.50 million of product missing year end shipping cut-off

·      Revenue mix

|   | 2021 | 2020 | 
| d2w Masterbatch | £7.19 million | £7.27 million | 
| d2p Masterbatch | £0.45 million | £0.47 million | 
| Finished Products | £1.40 million | £1.80 million | 
| Other | £0.12 million | £0.23 million |

·      R&D spend expensed and/or capitalised £0.66 million (2020: £0.60 million)

·      Gross profit £3.59 million (2020: £4.11 million)

·      Reported loss before tax £1.53 million (2020: £0.44 million)

·      Basic loss per share 0.81p (2020: 0.19p)

·      Cash used in operations £0.60 million (2020: £1.44 million)

**Business highlights:**

**d2p Technologies**

·      US FDA further approval for antibacterial plastic technology with greater
loading and wider film use in bread packaging

·      Canadian Health approval obtained for antibacterial bread packaging films

·      Meditech nitrile glove manufacturing, marketing and distribution agreements

·      Antimicrobial ten-minute Coronavirus kill rate achieved

·   Substantial progress in many product areas including an increase in customer
trials and product-tests currently underway.

·      Significant potential sales identified in many of the current pipeline projects

**Corporate**

·      Major Expansion with Joint Venture into India with Indorama Corporation –
completed in February 2022

·   Investment continues in the sales team, and new Head of Innovation appointed
to accelerate the commercialisation of the Group’s growing portfolio of new and 
highly innovative products

·      Several patent applications filed to protect our IP as many new products 
reach commercialisation

·      Small Caps Award: ESG Company of the Year

**Chairman’s Statement**

2021 was a year of contrasting results. These financial results do not reflect the
transformational effort and success that was achieved in many of our high value 
development projects that are mainly customer led. We had expected these material
changes to positively impact 2021 but repeated and unpredictable lockdowns created
logistical and resource difficulties, which delayed the commencement of some large
and valuable projects.  However, with the vaccination programmes being rolled out
around the world, we now anticipate many of these projects will advance to commercialisation
much faster, which will start to have a transformational effect on the business.

The progress in customer driven development projects, many of which are significant
both from a revenue perspective, but crucially also underpin long term relationships,
provide the Group with real optimism that substantial revenue growth in the short
and longer term will be achieved. 

Group revenues for the year ended 31 December 2021 were £9.16 million (2020: £9.77
million). Further, revenues of £0.50 million missed the year end cut-off due to 
shipping congestion and delayed sailings. Of the recognised revenues for 2021, both
d2w and d2p were on a par with the previous year, with total year-on-year revenue
reduction mainly in respect of PPE items such as gloves with the compliance, sampling
and regulatory process taking much longer than anticipated. Together with congestion
and delays, shipping charges were also high during the period, and this higher cost
so far continues in 2022.

The business could maintain sales at approximately £9 million on a significantly
reduced cost base (estimated at £2 million lower); however, the Board’s confidence
in the outlook for the Group’s products, means we continue to invest in the Group’s
infrastructure, staff and R&D so that the business is able to fully maximise the
growth potential for the customers and markets already secured.

Investment into d2w, our biodegradable technology, continued during the year with
further independent certification to prove biodegradability and no persistent microplastics
on land and oceans, together with specific advocacy teams that are focussing on 
several important markets such as Latin America where the legislation process is
moving towards changes in laws that we believe will encourage the use of d2w type
technologies. It is pleasing to see in this region a positive commercial result 
from this medium-term investment strategy that has helped increase volumes by 25%
with an indication of further strengthening going forward.  In the Middle East, 
volumes were consistent with 2020 which was a good result as local plastic production
volumes were reported to have decreased by more than 50% due to Covid-19 restrictions.
We are also starting to see business return to pre-Covid-19 levels, and very soon
the start of a biodegradable enforcement programme by the Saudi national standards
organisation (which is more easily capable of being enforced following the cessation
of Covid-19 restrictions which have been in place during the last 2 or so years).
This we believe will also have a positive effect in surrounding countries and further
afield.

Sales for d2w have now commenced in India following completion in February 2022 
of the agreement in November 2021 to form a joint venture with Indorama Corporation
together with a local manufacturing agreement. This opens an exciting and large 
opportunity as the Indian government are taking immediate steps to control plastics
through new regulations that are expected to encourage the use of compostable and
biodegradable products like d2w. We look forward to providing further updates on
this regulation and commercial progress during 2022.

Investment into the many d2p “Designed to Protect” technologies and products has
continued throughout the year and whilst various programmes have progressed, the
enhancement of the US FDA approval is undoubtedly a significant milestone upon which
we will build our sales. Health Canada adds to this important food approval process
for use in bread packaging, thus opening two very large potential markets plus other
territories which follow FDA regulations. Although the commercial and sales development
process has been slower than anticipated, it continues to progress satisfactorily.
Long-term sales based upon current negotiations could potentially be a multiple 
of the Group’s current revenue. Further announcements are expected to be made in
the near term and throughout 2022.

In addition to plastic packaging applications, we continued to advance the development
and regulatory process of a d2p antimicrobial/antiviral nitrile glove with Meditech.
This process is expected to complete during 2022 following which we will start marketing
and selling to known customers in the UK, EU and USA where we have already ongoing
negotiations dependent on the completion of regularity approvals.

I would like to thank the Board, our staff, and distributors for all their hard 
work in advancing the business through globally challenging times into a period 
where many of our developments become commercial and cash-generative.

The Board continue to be optimistic that the future performance of Symphony Environmental,
particularly financially will improve materially during 2022 and beyond.

N Clavel

Interim Chairman

Share on:
